Novel imidazotrizinones of general formula (I), a method for the production and the pharmaceutical use thereof are disclosed.
新型咪唑三唑酮的一般化学式(I),以及其生产方法和药用方法。
2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
申请人:Bayer Aktiengesellschaft
公开号:US06362178B1
公开(公告)日:2002-03-26
The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
7-alkyl- and cycloalkyl-substituted imidazotriazinones
申请人:Bayer Aktiengesellschaft
公开号:US06476029B1
公开(公告)日:2002-11-05
The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
申请人:Niewohner Ulrich
公开号:US20050070541A1
公开(公告)日:2005-03-31
The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
申请人:Bayer Schering Pharma AG
公开号:EP2295436A1
公开(公告)日:2011-03-16
Die 2-Phenyl-substituierten Imidazotriazinone mit kurzen, unverzweigten Alkylresten in der 9-Position werden aus den entsprechenden 2-Phenyl-imidazotriazinonen durch Chlorsulfonierung und anschließender Umsetzung mit den Aminen hergestellt. Die Verbindungen hemmen cGMP-metabolisierende Phosphodiesterasen und eignen sich als Wirkstoffe in Arzneimitteln, zur Behandlung von cardiovaskulären und cerebrovaskulären Erkrankungen und/oder Erkrankungen des Urogenitalsystems, insbesondere zur Behandlung der erektilen Dysfunktion.